Loading
Latest filing published 20 Aug 2025 for Tonix Pharmaceuticals Holding Corp., €7,724.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
James Treco discloses dealings in Tonix Pharmaceuticals Holding Corp. to SEC (Form 4). In total, 4 filings cover trades dated from 14 August 2020 to 20 August 2025.
Every open-market trade on record is a purchase: 3 purchases worth €16k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2025 alone, the filings show 1 purchase and no sales.
The median purchase comes to €4,100. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -38.4%. Past outcomes like these are no guarantee of what comes next.
On 20 August 2025 came the latest disclosure, an open-market purchase for €7,724 in Tonix Pharmaceuticals Holding Corp. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations